Fresenius SE & Co. (OTCMKTS:FSNUY) Shares Gap Up – Here’s What Happened

Posted by Donna Armstrong on Sep 30th, 2026

Fresenius SE & Co. (OTCMKTS:FSNUY – Get Free Report)’s share price gapped up prior to trading on Wednesday. The stock had previously closed at $12.62, but opened at $13.44. Fresenius SE & Co. shares last traded at $12.8090, with a volume of 14,732 shares traded.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Fresenius SE & Co. in a report on Thursday, August 6th. Morgan Stanley reissued an “overweight” rating on shares of Fresenius SE & Co. in a report on Tuesday, July 21st. Three equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy”.

Read Our Latest Analysis on Fresenius SE & Co.

Fresenius SE & Co. Stock Performance

The company has a market cap of $28.84 billion, a PE ratio of 16.21 and a beta of 0.62. The firm’s 50 day moving average is $13.18 and its 200-day moving average is $12.41. The company has a debt-to-equity ratio of 0.41, a quick ratio of 0.97 and a current ratio of 1.28.

Fresenius SE & Co. (OTCMKTS:FSNUY – Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $0.24 EPS for the quarter, missing the consensus estimate of $0.25 by ($0.01). The company had revenue of $6.91 billion for the quarter, compared to analysts’ expectations of $6.65 billion. Fresenius SE & Co. had a return on equity of 10.25% and a net margin of 6.67%. On average, research analysts anticipate that Fresenius SE & Co. will post 1.08 earnings per share for the current fiscal year.

Fresenius SE & Co. Company Profile

(Get Free Report)

Fresenius SE & Co KGaA is a German healthcare company headquartered in Bad Homburg, Germany. The group develops and provides products and services for hospitals, outpatient care providers and patients, with operations focused primarily on healthcare products and hospital services.

Its Fresenius Kabi business supplies medicines and technologies used in infusion therapy, clinical nutrition and transfusion medicine. Its portfolio includes intravenous drugs, generic medicines, biosimilars, infusion systems, medical devices and products for parenteral and enteral nutrition.

Fresenius also operates hospitals through Helios, which manages acute-care and rehabilitation facilities in Germany and hospitals and other healthcare services in Spain through the Quirónsalud network.